JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DIPALMA, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DIPALMA, J. R.
Journal of Pharmacology And Experimental Therapeutics, Vol. 113, Issue 2, 125-131, 1955
Copyright © 1955 by American Society for Pharmacology and Experimental Therapeutics


THE PHARMACOLOGY OF N-(4-METHOXYBENZYL)-ISOQUINOLINIUM CHLORIDE, WIN 2173, WITH PARTICULAR REFERENCE TO ITS CARDIAC EFFECTS

JOSEPH R. DIPALMA 1

1 Department of Pharmacology, Hahnemann Medical College and Hospital, Philadelphia, Pennsylvania

N-(4-methoxybenzyl)-isoquinolinium chloride is an aromatic quaternary ammonium compound which has weak ganglionic and neuromuscular blocking effects. Its main action is a positive inotropic and chronotropic effect on the heart which has been demonstrated in this investigation on isolated cat atrium, intact dogs and humans. These effects are more pronounced under conditions of hypothermia. Local anesthesia comparable to that obtainable by procaine is produced by intradermal injection. However, WIN 2173 produces a local reaction suggestive of histamine release.

Unlike quinidine and similar drugs, WIN 2173 does not protect against epinephrine-hydrocarbon induced arrhythmias. However, it is much more potent than quinidine in raising the threshold of electrically indluced atrial fibrillation in the cat.

The drug is well tolerated in intact unanesthetized animals and humans provided the dose does not exceed 5 mgm./kgm. intravenously or intramuscularly. Dilation of the pupils, flushing and occasionally vertigo are encountered in humans but are transient. The clinical trial for the cure of human arrhythmias will be the subject of a future report.

Submitted on September 9, 1954







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1955 by the American Society for Pharmacology and Experimental Therapeutics.